Lack of a pharmacokinetic interaction between azithromycin and chloroquine.
A study was conducted to investigate a possible pharmacokinetic interaction between azithromycin and chloroquine. Twenty-four subjects received azithromycin, 1,000 mg a day for three days, followed by a washout period, then azithromycin, 1,000 mg plus chloroquine 600 mg base on days 1 and 2, and azithromycin, 1,000 mg plus chloroquine 300 mg base on day 3 of the final period. A second group of 16 subjects received chloroquine, 600 mg base on days 1 and 2, then 300 mg base on day 3. Blood samples were obtained serially up to 624 hours after the day 3 dose in each period. Log transformed maximum concentration and area under the curve values of azithromycin and chloroquine were compared using 90% confidence intervals calculated from appropriate analysis of variance models. Ninety percent confidence intervals for all pharmacokinetic parameters were contained within the interval 80-125%, which indicates the absence of a clinically relevant pharmacokinetic interaction.
Cook
Jack A
JA
Pfizer Global Research and Development, Pfizer Incorporated, Ann Arbor, Michigan, USA. Jack.Cook@pfizer.com
Randinitis
Edward J
EJ
Bramson
Candace R
CR
Wesche
David L
DL
D000328:Adult; D000818:Animals; D000962:Antimalarials / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D019540:Area Under Curve; D017963:Azithromycin / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D002738:Chloroquine / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics*; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005260:Female; D006207:Half-Life; D006801:Humans; D016778:Malaria, Falciparum / Q000097:blood* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D000962:Antimalarials; D017963:Azithromycin; D002738:Chloroquine